NASDAQ: LGND · Biotechnology
Ligand Pharmaceuticals (LGND) fair value and price range
As of 14 Nov 2026, Faircurve's model values Ligand Pharmaceuticals (LGND) at $282.99 a share. The stock last closed at $301.71, which puts the model's fair value 6.2% below the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 16 Nov 2026. Ligand Pharmaceuticals Incorporated.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 held the fair value at $282.99, within 1% of the run of 7 Nov 2026.
What the model makes of itThe price of $301.71 is 6.2% above it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 25 Feb 2027. Options prices imply a move of about 13% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give LGND?
The calibrated range for LGND over 63 trading days is $261.39 to $350.78. It sits around the last close, and its width comes from the volatility that LGND's own options imply (43% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $156.29 to $473.44. In 45% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Ligand Pharmaceuticals Incorporated (LGND) operates as a biopharmaceutical entity. It sources and advances technologies to help pharmaceutical companies worldwide discover and develop new therapeutic solutions.
Faircurve's model puts the fair value of Ligand Pharmaceuticals at $282.99 a share on 14 Nov 2026. This is the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $280.59, so the fair value moved +0.9%. The sheet gives no reason for the move. The calibrated range over 63 trading days is $261.39 to $350.78. It is built around the price from the volatility the stock's own options imply, and calibrated weekly against realised prices from 8,038 past valuations. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
Ligand scores 47 out of 100 on the model's overall quality measure, a composite of six factors scored against comparable companies. Three factors stand out. Earnings quality scores 85, with free cash flow to net income at 1.76x against a peer median of 1.08x. Growth quality scores 83, with trailing revenue growth at 60.4% against a peer median of 8.0%. Capital discipline scores 82, with net buybacks at 1.0% of market value against a peer median of 0.1%. The model compares the company with Protagonist Therapeutics, Inc. (PTGX), TG Therapeutics, Inc. (TGTX) and BioMarin Pharmaceutical Inc. (BMRN).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does LGND report earnings, and how has the stock reacted?
Ligand Pharmaceuticals's next earnings report is scheduled for 25 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 10.1% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. LGND's 30 day implied volatility works out to about 12.5% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across LGND's last 8 reports, ignoring direction, was 3.6%.
What the options market has priced for a month's move in LGND
How does LGND score on business quality?
Ligand Pharmaceuticals's overall quality score is 47 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 10 | 1.4%ROIC | 39.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 85 | 1.76xFCF / net income | 1.08x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 83 | 60.4%Revenue growth, trailing | 8.0% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 82 | 1.0%Net buybacks / market value | 0.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 23 | 13.64xNet debt / EBITDA | -0.34x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 0 | 14.8 ptsEBITDA margin downside volatility, 5y | 5.6 pts |
How does LGND compare with similar companies?
The companies in biotechnology closest to Ligand Pharmaceuticals in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. | $44.21 | $53.67 | +21.4% | Low evidence grade |
| PTCT PTC Therapeutics, Inc. | $60.97 | $74.62 | +22.4% | Low evidence grade |
| CYTK Cytokinetics, Incorporated | $53.17 | $63.03 | +18.5% | Low evidence grade |
| PTGX Protagonist Therapeutics, Inc. | $124.83 | $104.97 | -15.9% | Overvalued |
| KRYS Krystal Biotech, Inc. | $297.90 | $352.42 | +18.3% | Low evidence grade |
| TGTX TG Therapeutics, Inc. | $62.76 | $75.36 | +20.1% | Undervalued |
| BMRN BioMarin Pharmaceutical Inc. | $57.99 | $69.09 | +19.1% | Undervalued |
| HALO Halozyme Therapeutics, Inc. | $96.50 | $111.93 | +16.0% | Low evidence grade |
What the comparable companies' multiples alone would give for LGND, the peer-implied price, is $100.43 a share on this run. The fair value weighs that against the company's own multiple.
Ligand Pharmaceuticals at a glance
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions.
- Market value
- $6.2B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $373M
- Consensus revenue growth, next fiscal year
- +8.9%
- Analysts with estimates
- 7
- Beta to the US market
- 0.80
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Ligand Pharmaceuticals on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for LGND was $280.59. As of 14 Nov 2026 it is $282.99, a change of +0.9%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Ligand Pharmaceuticals's valuation
Is Ligand Pharmaceuticals stock undervalued or overvalued?
Faircurve's model puts LGND's fair value at $282.99 a share against a last close of $301.71, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is LGND's fair value?
$282.99 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $156.29 to $473.44.
What price range does the model give LGND?
$261.39 to $350.78 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Ligand Pharmaceuticals report earnings next?
The next report is scheduled for 25 Feb 2027. Companies can move their dates.
How much has LGND moved on past earnings reports?
Across its last 8 reports the median two session move was 3.6%, ignoring direction. The largest was +6.4% around the report of 6 Nov 2025.
How confident is the model in this valuation?
The model's evidence grade for LGND is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on LGND
The model holds no idea open on LGND today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on LGND with their outcomes. A free account is enough.